title: AZD5213: a novel histamine H3 receptor antagonist permitting high daytime and low nocturnal H3 receptor occupancy, a PET study in human subjects.
abstract: The histamine H3 receptor represents an appealing central nervous system drug target due to its important role in the neurobiology of cognition and wake-sleep regulation. The therapeutic benefit of H3 antagonists/inverse agonists may be hampered by disruption of sleep that has been observed in humans with prolonged high H3 receptor occupancy (H3RO), extending into night-time. AZD5213 is a highly selective H3 antagonist (in vitro inverse agonist) developed to achieve a pharmacokinetic profile permitting circadian fluctuations of H3RO. Its efficacy has been demonstrated in rodent behavioural models of cognition. In human subjects, AZD5213 was safe and well tolerated following repeated doses (1-14 mg/d) and demonstrated a short (∼5 h) half-life. In this PET study H3RO was measured using the radioligand [11C]GSK189254 ([11C]AZ12807110) in seven young male volunteers following single doses of AZD5213 (0.05-30 mg). H3RO was calculated using the Lassen plot method. The plasma concentrations and the affinity constant (K i,pl 1.14 nmol/l, corresponding to the plasma concentration required to occupy 50% of available receptors) were used to estimate the H3RO time-course. AZD5213 showed dose and concentration dependent H3RO ranging from 16 to 90%. These binding characteristics and the pharmacokinetic profile of AZD5213 indicate that high daytime and low night-time H3RO could be achieved following once daily oral dosing of AZD5213. Fluctuations of H3RO following circadian rhythm of the histamine system may be expected to reduce the risk of sleep disruption while maintaining daytime efficacy. AZD5213 may thus be an optimal compound to evaluate the clinical benefit of selective H3 antagonism in cognitive disorders.
authors.affiliation: AstraZeneca, Södertälje, Sweden. Aurelija.Jucaite@astrazeneca.com
authors.forename: Aurelija
authors.initials: A
authors.lastname: Jucaite
authors.forename: Akihiro
authors.initials: A
authors.lastname: Takano
authors.forename: Emma
authors.initials: E
authors.lastname: Boström
authors.forename: Karl-Gustav
authors.initials: KG
authors.lastname: Jostell
authors.forename: Per
authors.initials: P
authors.lastname: Stenkrona
authors.forename: Christer
authors.initials: C
authors.lastname: Halldin
authors.forename: Märta
authors.initials: M
authors.lastname: Segerdahl
authors.forename: Svante
authors.initials: S
authors.lastname: Nyberg
mesh_terms: D000328:Adult; D001345:Autoradiography; D001552:Benzazepines / Q000493:pharmacokinetics; D001921:Brain / Q000187:drug effects*; D002250:Carbon Radioisotopes / Q000097:blood / Q000493:pharmacokinetics; D002940:Circadian Rhythm / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D054828:Histamine H3 Antagonists / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D006801:Humans; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D049268:Positron-Emission Tomography; D011485:Protein Binding / Q000187:drug effects; D011869:Radioligand Assay; D018100:Receptors, Histamine H3 / Q000187:drug effects / Q000378:metabolism*; D055815:Young Adult
chemical_list: D001552:Benzazepines; D002250:Carbon Radioisotopes; D054828:Histamine H3 Antagonists; D018100:Receptors, Histamine H3; D009536:Niacinamide; C521312:6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-pyridinecarboxamide